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Abstract
Background: In the present study, we investigated the effect of Origanum majorana ethanolic extract on the survival of the
highly proliferative and invasive triple-negative p53 mutant breast cancer cell line MDA-MB-231.
Results: We found that O. majorana extract (OME) was able to inhibit the viability of the MDA-MB-231 cells in a time- and
concentration-dependent manner. The effect of OME on cellular viability was further confirmed by the inhibition of colony
growth. We showed, depending on the concentration used, that OME elicited different effects on the MDA-MB 231 cells.
Concentrations of 150 and 300 mg/mL induced an accumulation of apoptotic–resistant population of cells arrested in
mitotis and overexpressing the cyclin-dependent kinase inhibitor, p21 and the inhibitor of apoptosis, survivin. On the other
hand, higher concentrations of OME (450 and 600 mg/mL) triggered a massive apoptosis through the extrinsic pathway,
including the activation of tumor necrosis factor-a (TNF-a), caspase 8, caspase 3, and cleavage of PARP, downregulation of
survivin as well as depletion of the mutant p53 in MDA-MB-231 cells. Furthermore, OME induced an upregulation of c-H2AX,
a marker of double strand DNA breaks and an overall histone H3 and H4 hyperacetylation.
Conclusion: Our findings provide strong evidence that O. majorana may be a promising chemopreventive and therapeutic
candidate against cancer especially for highly invasive triple negative p53 mutant breast cancer; thus validating its
complementary and alternative medicinal use.
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Introduction
Breast cancer is the most frequently diagnosed cancer among
women and ranks second as a cause of cancer death in women
after lung cancer. An estimated 226,870 new cases of invasive
breast cancer are expected to occur among women in the US
during 2012 [1]. Plants have been shown to be an excellent source
of new drugs, including anticancer agents. Identification and
development of new chemotherapeutic agents from plants have
gained significant recognition in the field of cancer therapy and
become a major area of experimental cancer research. The
majority of the chemotherapeutic drugs used in cancer treatment,
is either from plant origin or chemically-altered plant products and
phytochemicals [2]. In fact, plant-derived anticancer drugs are
much more effective and do not have large side-effect conse-
quences compared to synthetic drugs. Examples of anticancer
drugs derived from plants and currently in clinical use include the
vinca alkaloids vinblastine and vincristine were isolated from
Catharan roseus, the terpene paclitaxel from Taxus brevifolia Nutt.,
and the DNA topoisomerase I inhibitor camptothecin from
Camptotheca acuminata [3].
Phytochemicals exert their chemoprevention effect of carcino-
genesis through several mechanisms. These include inhibition of
genotoxic effects, increased antioxidants and anti-inflammatory
activity, modulation of cellular signaling pathways and altering
gene expression to inhibit cell proliferation and/or induce
apoptosis [4].
It is well known that cancer is pathological condition that has
been associated with aberrantly regulated apoptosis. It is currently
accepted that certain phytochemicals and whole plant extracts can
affect the overall process of carcinogenesis by multiple mecha-
nisms. Since apoptosis provides a physiologic protective mecha-
nism for eliminating genetically damaged cells, initiated cells or
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cells progressed to malignancy; phytochemicals affecting apoptosis
can have an important effect on carcinogenesis [5].
Increasing number of studies have shown evidence of chemo-
prevention and chemotherapy by stimulating apoptosis in pre-
cancerous and cancerous cells in vitro or in vivo suggesting that
apoptosis is likely to be a crucial mechanism to suppress
carcinogenesis. Epigallocatechin gallete (EGCG) (from green
tea), curcumin (Curcuma longa), quercetin (Vegetable and fruits)
are some examples of chemopreventive agents, from natural
origin, that induce apoptosis in carcinogenesis models or in human
chemoprevention trials [6,7]. Also, a number of plant extracts,
such as blueberry [8], mushroom [9], gingerol [10], to name just a
few, were shown to have anticancer effects against breast cancer
cells.
Origanum majorana belongs to the family Lamiaceae. It is
commonly known as marjoram. It is a perennial herb and
widespread worldwide. A large number of known species of the
genus Origanum are utilized worldwide as spices and flavoring
agents and has a long history of both culinary and medicinal use.
O. majorana is used as a home remedy for chest infection, cough,
sore throat, rheumatic pain, nervous disorders, stomach disorders,
cardiovascular diseases, and skin care [11,12]. Many of such
traditional uses of marjoram species were confirmed in several
studies utilizing both in vitro and in vivo approaches.
Several reports indicate that O. majorana is very rich in phenolic
compounds. The high phenolics content in Origanum has a capacity
to scavenge free radicals and shown to be associated with the
strong antioxidant activity [13]. O. marjorana was shown to contain
phenolic terpenoids (thymol and carvacrol), flavonoids (diosmetin,
luteolin, and apigenin), tannins, hydroquinone, phenolic glycosides
(arbutin, methyl arbutin, vitexin, orientin, and thymonin) and
triterpenoids (ursolic acid and oleanolic acid) [14].
O. majorana has been reported to exhibit a significant anti-
microbial activity [15]. Several studies have also demonstrated
that ethanolic, aqueous extracts and essential oil of O. majorana
could protect against liver and kidney damage and genotoxicity
induced by lead acetate [16–18]. O. majorana has also been found
to inhibit platelet adhesion aggregation and secretion [19].
Furthermore, it has been shown that this plant exerts a low
cytotoxicity on several hepatoma cell lines [20]. It has been shown
by Al Harbi that extract of O. majorana reduced the side effects
induced by cyclophosphamide, an established anticancer drug,
without altering its cytotoxicity [12].
In the present study, we investigated the effect of Origanum
majorana ethanolic extract (OME) on breast cancer cells. We
examined the effects of OME on cell viability, cell cycle, apoptosis,
and the levels of several cell cycle and apoptosis control proteins in
the highly proliferative and invasive Estrogen Receptor (ER)-
negative, mutant p53 breast cancer cell lines MDA-MB-231. Our
results demonstrate that OME can inhibit the growth of the MDA-
MB-231 cells by causing cell cycle arrest and apoptosis dependent
on the downregulation of survivin and mutant p53.
Materials and Methods
Preparation of the Origanum majorana Ethanolic Extract
Origanum marjorana commonly known as ‘‘marjoram’’ and used
as a culinary herb, was obtained from a private commercial farm
located in the Tyre region of Lebanon. All necessary permits were
obtained for the harvesting of the leaves. The identity of the OM
dried leaves used in this study was further confirmed by a plant
taxonomist. 5.0 g of the dried leaves were ground to a fine powder
using a porcelain mortar and pestle. The powder was suspended in
100 mL of 70% absolute ethanol and the mixture was kept in the
dark for 72 hours at 4uC in a refrigerator without stirring. The
mixture was then filtered through a glass sintered funnel and the
filtrate was evaporated to dryness using a rota-vapor at room
temperature. The green residue was kept under vacuum for 2–3
hours and its mass was recorded.
Cell Culture and Reagents
Human breast cancer cells MDA-MB-231 were maintained in
DMEM (Hyclone). The culture media was supplemented with
10% fetal bovine serum (invitrogen), 100 U/ml penicillin/
streptomycin (invitrogen). Antibodies to p21 (556431), PARP
(556494) were obtained from BD Pharmingen. Antibodies to
phosphor-H2A.X (ser139) (07–164), acetyl-Histone H3 (06–599),
acetyl-Histone H4 (06–866) and phosphor-Histone H3 (ser10) (05–
1336), p53 (E26, 04–241) and cyclin B1 (05–373) were obtained
from Millipore. Antibodies to survivin (sc-17779), b-actin (C4, sc-
47778), goat anti-mouse IgG-HRP (sc-2005) and goat anti-rabbit
IgG-HRP (sc-2004) were obtained from Santa Cruz Biotechnol-
ogy, Inc. Antibody to TNF-a (ab9739) was obtained from abcam
and antibodies AlexaFluor 488 goat anti-rabbit IgG (H+L)
(A11008), AlexaFluor 594 goat anti-mouse IgG (H+L) (A11005)
were obtained from invitrogen.
Cellular Viability
Cells were seeded in triplicate in 96-well plates at a density of
5,000 cells/well into 96-well plates. After 24 h of culture, cells
were treated with increasing concentrations of OME or equal
volume of vehicle (ethanol) as control and incubated for the
indicated time period. Cell viability was determined using a
CellTiter-Glo Luminescent Cell Viability assay (Promega Corpo-
ration, Madison, USA), based on quantification of ATP, which
signals the presence of metabolically active cells. Luminescent
signal was measured using Berthold FB12 Luminometer. Data
were presented as proportional viability (%) by comparing the
treated group with the untreated cells, the viability of which is
assumed to be 100%.
Measurement of Caspase 3/7, 8 and 9 Activities
MDA-MB-231 cells were seeded at the density of 5,000 cells/
well into 96-well plate in triplicate and treated with indicated
concentrations of OME or equal volume of vehicle (ethanol) as
control for 24 and 48. Caspase-3/7, 8 and 9 activities were
measured using a luminescent caspase-Glo 3/7, caspase8 and
caspase 9 assay kit (Promega Corporation, Madison, USA)
following the manufacturer’s instructions. Briefly, caspase reagents
were added to triplicate wells of a 96-well plate which was then
mixed in an orbital shaker and incubated for 2.5 h at room
temperature in the dark. Luminescent signal was measured as
described above.
Flow Cytometric Analysis of Cell Cycle
MDA-MB 231 cells were seeded in 100 mm culture dishes and
cultured for 24 h before addition of various concentrations of
OME or equal volume of vehicle (ethanol) as control. After
incubation for the indicated time, cells were harvested by trypsin
release, washed twice with ice-cold PBS, resuspended in 500 ml
PBS, fixed with an equal volume of 100% ethanol and incubated
for at least 12 h at 220uC. Before flow cytometry analysis, cells
were pelleted, washed twice with PBS, permeabilized in 0.1%
Triton X-100/PBS for 15 min on ice, pelleted and then
resuspended in PBS containing 40 mg/ml propidium iodide and
25 mg/ml RNase A, and incubated at 37uC for 30 min. Cell
samples were analyzed on the BD FACSCanto II (Becton
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Dickinson). Data acquisition was performed using FACSDiva 6.1
software. Percentage of cells in G1, S and G2/M phases were
determined using the FlowJo software.
Immunofluorescence Staining
MDA-MB 231 cells (36104) were grown in complete media on
4 well labtek chamber slide (Nunc) for 24 h, then treated with the
indicated concentrations of OME or equal volume of vehicle
(ethanol) as control for 24 h. Cells were then fixed in 10% formalin
solution (4% paraformaldehyde) (Sigma-Aldrich) for 5 min at RT
followed by permeabilization in PBS containing 0.1% Triton X-
100 for 5 min at RT. Cells were then washed three times with
PBS, blocked with 5% nonfat dry milk in PBS for 30 min at RT
and incubated with the primary antibody diluted, at the
concentration suggested by the manufacturer, in 1% nonfat dry
milk/PBS overnight at 4uC. Following overnight incubation, cells
were washed three times with PBS and placed for 1 h at RT in the
presence of rhodamine-conjugated or fluorescein-conjugated
secondary antibody diluted at 1:200 in 1% nonfat dry milk/
PBS. After washing with PBS, sample cells were mounted in
Fluoroschield with DAPI (Sigma-Aldrich) and examined under
Nikon Ti U fluorescence microscope.
Cell Extract and Western Blotting Analysis
Cells (1.86106) were seeded in 100 mm culture dishes and
cultured for 24 h before addition of various concentrations of
OME or equal volume of vehicle (ethanol) as control. After
incubation for the indicated times, cells were washed twice with
ice-cold PBS, released by scrapping, pelleted and lysed in RIPA
buffer supplemented with protease/phosphatase inhibitor cocktail.
Following incubation for 30 min on ice, the cell lysate was
obtained by centrifugation at 14,000 rpm for 20 min at 4uC.
Protein concentration of lysates was determined by BCA protein
assay kit (23225, Thermo Scientific) and the lysates were adjusted
with lysis buffer. Aliquots of 25 mg of total proteins were resolved
onto 10–12% SDS-PAGE. Proteins were transferred to nitrocel-
lulose membranes (88018, Thermo Scientific) and blocked for 1 h
at room temperature with 5% non-fat dry milk in TBST (TBS and
0.05% Tween 20). Incubation with specific primary antibodies was
performed in blocking buffer overnight at 4uC. Horseradish
peroxidise-conjugated anti-IgG was used as secondary antibody.
Immunoreactive bands were detected by ECL chemiluminescent
substrate (32209, Thermo Scientific). Membrane stripping by
incubating the membrane in Restore western blot stripping buffer
(21059, Thermo Scientific) according to the manufacturer’s
instructions.
Colony Formation Assay in Soft Agar
Assays were performed in six-well plates. The lower (base) layer
consisted of 1 ml 2.4% Noble agar. The base layer was overlaid
with a second layer consisted of 2.9 ml growth medium, 0.3%
Noble agar, and 36104 MDA-MB-231 cells. Agar at 50uC was
mixed with medium at 37uC, plated, and left to set for 10 min.
Then 2 ml of growth medium was added on the top of the second
layer. Plates were incubated at 37uC, humidified, and 5% CO2.
Cells were allowed to grow in absence of treatment for 14 days
until visible colonies were formed. Plates were fed twice a week
with 2 ml of regular complete growth medium (DMEM). After 2
weeks, plates were fed with medium containing either the
indicated concentrations of OME or equal volume of vehicle
(ethanol) as control and the colonies were allowed to grow for one
more week. Following treatment, the plates were washed twice
with PBS and then colonies were fixed with 10% ice-cold
methanol for 10 min and washed once with PBS. The colonies
were allowed to stain for 1 hr in solution containing 2% Giemsa.
The size of the colonies were measured, counted using a
microscope (10X) and the colony size was categorized as Large
(.200 mM) or small (50–200 mM). Colony sizes were expressed as
a percentage of total counted colonies and then compared to the
vehicle treated controls (ethanol). The experiment was repeated
two times.
Statistical Analysis
Results were expressed as means 6 S.E.M. of the number of
experiments. A Student’s t-test for paired or unpaired values was
performed and a p value of ,0.05 was considered statistically
significant.
Results
O. majorana Extract Inhibits the Viability of the MDA-MB-
231 Breast Cancer Cells
To examine the anticancer activity of Origanum majorana extract
(OME) on breast cancer cells, we first measured the effect of
various concentrations of the extract (0, 50, 150, 300, 450 and
600 mg/mL) on the proliferation of the MDA-MB-231 breast
cancer cell line (Figure 1A). Our results show that the exposure of
the MDA-MB-231 to OME decreased cellular viability in a
concentration- and a time-dependent manner. The IC50 (produc-
ing half-maximal inhibition) was approximately 350 mg/mL at
24 h and 400 mg/mL at 48 h treatment. The observation of the
OME-treated MDA-MB231 cells under light microscopy also
revealed that the number of cells decreased when the concentra-
tion increased. Furthermore, as shown in figure 1B, light
microscopy observation of MDA-MB231 cells treated with
concentrations of 150, 300 and 450 and 600 mg/mL OME,
underwent morphological changes characterized by a loss of their
epithelial morphology visible after 24 h of treatment. Echinoid
spikes and cellular rounding, characteristics of apoptotic cells were
also observed.
O. majorana Extract Leads to Mitotic Arrest and
Apoptosis in MDA-MB-231 Cells
The ability of an anticancer drug to affect cell cycle distribution
can provide information regarding its cytotoxic mechanism(s) of
action. For this reason, we investigated the effect of OME on cell
cycle distribution by flow cytometry. MDA-MB 231 cells were
treated with indicated concentrations of O. majorana for 24 h and
subjected to cell cycle analysis. At the concentration of 150 mg/
mL, OME caused obvious G/2M arrest on these cells (figure 2A).
Indeed, the population of G2/M increased significantly from 23 to
51.7% as the concentration of the OME increased to 150 mg/mL,
Figure 1. Effect of O. majorana extract on cell morphology and viability of human breast cancer cell MDA-MB-231 cells. Cells (56103
cells/well; 96-well plates) were cultured in DMEM supplemented with 10% Fetal bovine serum. (A) Cell viability (in percent) determined by using
CellTiter-Glo Luminescent Cell Viability assay, after incubation of the exponentially growing cells with the indicated concentrations of OME or equal
volume of vehicle (ethanol) as control for 24 and 48 h. (B) Micrograph of MDA-MB-231 cells, after 24 h incubation with various concentrations of
OME. Data represent the mean of at least three independent experiments carried out in triplicate. Student’s t test was performed to determine the
significance (*p,0.05, **p,0.005 and ***p,0.0005).
doi:10.1371/journal.pone.0056649.g001
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Figure 2. Induction of G2/M cell cycle arrest and apoptosis by O. majorana extract in MDA-MB-231 cells. (A) MDA-MB-231 cells (1.86106)
seeded on 100 mm culture dish were exposed various concentrations of O. majorana extract or equal volume of vehicle (ethanol) as control for 24 h.
Following treatment, cells were harvested, fixed, stained with propidium iodide, and analyzed for cell cycle distribution by flow cytometry. Data
represent the mean of three independent experiments. The percentage of cells in sub-G1 (apoptosis), G1, S and G2/M appears at the upper right of
each graph. (B) Expression of cell cycle regulator in OME-treated MDA-MB-231. Western blot analysis of phospho(ser10)-H3, and cyclin B1 in MDA-
MB231 cells exposed for 24 h to ethanol or indicated concentrations of OME. (C) Stimulation of caspase 3/7 activity in MDA-MB-231 cells after
exposure to OME (0–600 mg/mL) for 24 h and 48 h, relative to a similar amount of viable ethanol-treated cells. The relative caspase 3/7 activity was
normalized to the number of viable cells per well and is expressed as fold of induction compared to the control. (D) Concentration-dependent
induction of PARP cleavage in OME-treated MDA-MB231 cells. Cells were treated with or without increasing concentrations of the extract and
proteins were extracted as described in Materials and Methods. Western blot analysis was carried out using anti-PARP antibodies. (*p,0.05,
**p,0.005 and ***p,0.0005).
doi:10.1371/journal.pone.0056649.g002
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indicating that OME-treated MDA-MB-231 cells were arrested in
G2/M phase. A slight increase in the sub-G1 population (6.2%)
indicates that a small population of OME-treated MDA-MB-231
cells are undergoing cell death was also observed by these
concentrations. Similar results were obtained for 300 mg/mL of
OME (data not shown). Interestingly, at higher concentrations of
OME, flow cytometry analysis revealed a dramatic increase in the
apoptotic population (sub-G1 peak) raising from 0.9% in the
control to 48.4% and 56.7% in cells treated with 600 and 450 mg/
mL, respectively (Figure 2A).
To determine whether OME induced cell cycle arrest specif-
ically at mitosis or G2 phase, we examined the phosphorylation
status of histone H3 (Ser 10). Histone H3 is phosphorylated at
serine 10 during mitosis by aurora kinase and the phosphorylation
status of H3 is considered a marker of mitosis [21]. We therefore,
investigated the expression of p(ser10)H3 and found that
treatments 150 and 300 mg/mL of O. majorana significantly
increase the phosphorylation level of histone H3 (Figure 2B,
upper panel). This result indicates that OME induces mitotic
arrest of MDA-MB231 cells. Next, we investigated the mechanism
of OME-induced mitotic arrest. Accumulation of cyclin B1 is well
known to play an important role in G2/M transition. Knock-down
of cyclin B1 with siRNA produces cell cycle arrest predominantly
in the G2 phase [22], while an upregulation of cyclin B1 invokes
mitotic arrest [23]. We, therefore, investigated the protein level of
cyclin B1 in OME-treated MDA-MB-231 cells. We found that
treatment with these concentrations of OME leading to mitotic
arrest, caused also an increase of cyclin B1 protein in MDA-MB-
231 cells (Figure 2B, lowe panel), suggesting that cyclin B1
accumulation might play a crucial role in OM triggered mitotic
arrest. Taken together, our data reveal a differential concentration
effect of OME on cell cycle progression of the MDA-MB 231 cells.
Whereas, lower concentrations of OME (150 and 300 mg/mL)
induced a major mitotic arrest with a slight increase in the
apoptotic population, higher concentrations (450 and 600 mg/mL)
induced a massive cell death by apoptosis. The reduced cell
viability observed in MDA-MB231 cells treated with low
concentrations of OME, is possibly due to a large extent to an
inhibition of cell proliferation rather than to cell death.
Apoptosis in OME-treated MDA-MB-231 cells was further
examined by measuring caspase 3/7 activation in MDA-MB 231
cells treated with various concentrations (300, 450 and 600 mg/
mL) of OME after 24 h of treatment. A concentration- and time-
dependent activation of caspase 3/7 was detected in treated cells
(Figure 2C). Interestingly, cleavage of the poly(ADP-ribose)
polymerase (PARP) occurred only in cells treated with higher
(450 and 600 mg/mL) but not at lower concentrations (150 and
300 mg/ml) of OME (Figure 2D). It is noteworthy to mention that
at these lower concentrations of OME, only low apoptotic
induction rate was observed despite the detection of caspase 3/7
activation.
Concentration-dependent Regulation of Survivin
Expression by O. majorana Extract
Survivin, a member of the inhibitor of apoptosis protein (IAP)
family, plays an important role in both the regulation of cell cycle
and the inhibition of apoptosis. Survivin levels increase in G2/M
phase conferring resistance to apoptosis to the G2/M arrested
cells. However, a decrease in survivin levels sensitizes the cells to
apoptosis. Several studies have reported that survivin exerts its
negative effect on apoptosis by inhibiting the activity of caspase 3,
7 and 9. Therefore, we examined a possible involvement of
survivin in the cell cyle arrest and apoptosis triggered by OME.
Toward this, we have analyzed, by Western blotting, the
expression of survivin in response to various concentrations of
OME after 24 h treatment. Interestingly, we observed a differen-
tial concentration-effect of OME on survivin expression on the
MDA-MB-231 cells (Figure 3). We found that low concentrations
of OME led to a substantial increase in the level of survivin, while
higher concentrations caused a drastic decrease of survivin (99%).
Based on these results, we conclude that OME exerts a
concentration-dependent effect on MDA-MB-231 cells. Low
concentrations of OME induced a mitotically arrested cells
accompanied by survivin upregulation which, in turn, conferred
resistance to cell death to this population of cells, probably by
inhibiting the activity of caspase 3/7 which was monitored by the
absence of PARP cleavage at these concentrations. Treatment of
MDA-MB-231 cells with higher concentrations of OME caused a
dramatic decrease in survivin expression and consequently
sensitized MD-MB-231 cells to apoptosis.
O. majorana Extract Activates the Extrinsic Pathway for
Apoptosis via an Upregulation of TNF-a and Activation of
Caspase 8
Having shown that OME induces the activation of the effector
caspases 3/7, we looked at the activity of the initiator caspases of
the extrinsic and intrinsic cell death pathway, namely caspase 8
and caspase 9, respectively. Surprisingly, no caspase 9 activation
was detected in response to various concentrations of OME after
24 h of treatment (Figure 4A). On the other hand, caspase 8
activity increased in a concentration-dependent manner in
response to OME treatment (Figure 4A). This result demonstrates
that the apoptotic effect of the extract on MDA-MB-231 is
dependent on caspase 8 activity, which implicates only the
extrinsic cell death pathway since neither caspase 9 activation
(Figure 4A) nor a change in Bax/Bcl2 ratio (data shown) were
observed. After showing that the extrinsic cell death pathway is
implicated in OME-dependent apoptosis, we were then interested
in determining how this pathway is activated by OME. We
determined the changes in the expression level of the tumor
necrosis factor alpha (TNF-a) in response to OME after 24 h
treatment. Western blot analysis revealed a clear increase in the
level of TNFa in MDA-MB-231 cells in response to OME
treatment (Figure 4B). The upregulation of TNF-a was further
confirmed by immunofluorescence assay (Figure 4C). Even though
we have shown that OME exerts its effect via the activation of the
extrinsic pathway of cell death, we cannot rule out, at this stage,
Figure 3. Differential regulation of survivin expression by OME
in MDA-MB-231 cells. Western blot analysis showing a differential
effect on survivin expression by different concentrations of OME in
MDA-MB-231 cells. Whole cell protein were extracted from OME or
vehicle (ethanol)-treated cells and subjected to Western blot analysis, as
described in Materials and Methods, for survivin and b-actin (loading
control) proteins.
doi:10.1371/journal.pone.0056649.g003
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the possibility of OME-dependent apoptosis could also be
triggered by another mechanism.
O. majorana Lead to Depletion of Mutant p53 in MDA-
MB-231 and Upregulation of p21WAF1/CIP1
Next, we tested the effect of OME on the expression of the
tumor suppressor p53 in MDA-MB-231. Toward this aim, cells
were treated with various concentrations of OME and the protein
level of the mutant p53 determined. We found that low
concentrations of 150 and 300 mg/mL of OME led to a slight
increase in the protein level of mutant p53 (Figure 5, upper
pannel). Most importantly, Western blotting analysis revealed
apoptotic concentrations (450 and 600 mg/mL of OME) led to
almost complete depletion of mutant p53 in MDA-MB-231 cells.
This result is a potentially important finding because of the role of
mutant p53 protein in human cancers. Because mutant p53
renders cancer cells more resistant to anticancer drugs, abolishing
mutant p53 may therefore offer a promising approach for cancer
prevention and therapy.
Because p21 protein has been reported to inhibit growth and
apoptosis, we investigated whether the growth inhibition mediated
by low concentrations (150 and 300 mg/mL of OME) was also
associated with an induction of p21. Western blotting showed an
upregulation of p21 protein with at least 2.5 fold increase in cells
treated with low concentrations of OME, while a little or no effect
on p21 expression was observed with higher concentrations of
OME (Figure 5, lower panel). Based on that, we can postulate that
p21 upregulation contributes, at least partially, to the cell cycle
arrest observed with lower concentrations, while it has little or no
role in cell death occurring at higher concentrations of OME.
O. majorana Extract Induces Hyperacetylation of Histone
H3 and H4 in the MDA-MB 231 Cells
Previously, expression of p21 and increased histone hyperace-
tylation have been linked to apoptosis and to growth arrest.
Therefore, we examined the acetylation profile of histone H3 and
H4 in MDA-MB-231 in response to treatment for 24 h to
increasing concentrations of OME. As shown in figure 6A, the
time course analysis showed a gradual increase in acetylated
histones, H3 and H4. A marked overall increase in the acetylation
status of histone H3 and H4 was also detected by immunofluo-
rescence staining (Figure 6B). Altogether, these results showed that
OME induced hyperacetylation of histone H3 and H4.
Accumulation cH2AX, a Marker of Double Strand Breaks,
in O. majorana Extract Treated MDA-MB 231 Cells
We sought to investigate whether OME induced DNA damage
in MDA-MB-231 cells. For this purpose, MDA-MB 231 cells were
cultured for 6 and 24 h in complete media containing either
ethanol (control) or increasing concentrations of OME (75, 150,
300, 450 and 600 mg/mL). DNA damage was determined by
measuring the levels of phosphorylated H2AX (cH2AX) after 6
and 24 h of treatment of the MDA-MB-231 cells with OME.
Western blotting analysis revealed a time- and a concentration-
dependent increase in the levels of cH2AX in response to OME
treatment (Figure 7A), indicating an accumulation of double
strand breaks in these cells. The increase in DNA damage was also
assessed by immunofluorescence staining of cH2AX in cells
treated with 150, 300 and 450 mg/mL OME for 24 h. Figure 7C
clearly shows a concentration-dependent increase of cH2AX foci
in response to OME. Since the activation of cH2AX occured as
early as 6 h, a time in which no cell death (data not shown) or
caspase 3/7 activation were observed (Figure 7B), this rules out the
possibility that the resulting DNA damage is a consequence of
DNA fragmentation resulting from caspases’ activities and further
confirms the potential of this OME extract to induce double strand
DNA breaks in a dose-dependent manner.
O. majorana Inhibits Colony Growth of MDA-MB-231
To further confirm the inhibitory potential of O. majorana on
MDA-MB 231 cells, we sought to determine if OME could inhibit
the further growth of already formed MDA-MB-231 colonies. For
this purpose, MDA-MB-231 cells were first allowed to grow and
form visible colonies in absence of treatment. After 14 days of
growth, colonies were incubated with ethanol as control and with
OME and allowed to grow for one more week. Figures 8 shows
that the size of the ethanol-treated (control) colonies kept growing
compared to the size of the two weeks colonies; more large
colonies were obtained in the three weeks plate, while less small
colonies were counted, indicating that small colonies became
larger in size. Interestingly, OM-treated colonies shows regression
in colony size compared to the two weeks colonies. In OM-treated
plates, the number of large size colonies counted was less than
what was obtained in the two weeks plate, while the number of
Figure 4. O. majorana induces apoptosis by activation of caspase 8 and upregulation of TNF-a. (A) O. majorana extract induces an
activation of caspase 8 but not caspase 9 in MDA-MB-231 cells. MDA-MB-231 cells were incubated with various concentrations of the extract for 24 h.
The caspase activation induced by the OME was assayed as described under Materials and methods. The relative caspase 8 and 9 activity was
normalized to the number of viable cells per well and is expressed as fold of induction compared to the control. (B) Western blot analysis showing an
increase in cellular TNF-a protein in the MDA-MB-231 cells treated with OME. Whole cell protein were extracted from OME-treated cells or vehicle
(ethanol)-treated cells and subjected to Western blot analysis, as described in Materials and Methods, for TNF-a and b-actin (loading control) proteins.
(C) Immunofluorescence staining for TNF-a in OME-treated MDA-MB- 231cells. Cells were treated with 150 and 300 mg/mL of the extract for 24 h,
fixed, permeabilized, and then processed for immunofluorescence using antibodies against TNF-a protein. DAPI was used as a nuclear stain. (*p,0.05
and **p,0.005).
doi:10.1371/journal.pone.0056649.g004
Figure 5. Expression levels of mutant p53 and p21 in O.
majorana-treated MDA-MB-231cells. Cells were treated with
various concentrations of (150, 300, 450 and 600 mg/mL) of OME or
equal volume of vehicle (ethanol) as control for 24h and the expression
of mutant p53, p21 and b-actin were estimated by Western blot.
doi:10.1371/journal.pone.0056649.g005
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small colonies was significantly greater, suggesting size regression
in the large colony induced by OME. This result along with the
viability and flow cytometry data confirm the anti-cancer effect of
OME on the triple negative mutant p53 MDA-MB-231 breast
cancer cells.
Discussion
Common cancer treatment drugs aim at inhibiting the cell cycle
progression and at inducing cell death and apoptosis. Cancer
chemoprevention through these two events (cell cycle arrest and
apoptosis) has been reported for several natural compounds [6–
10].
In the present study, we have shown that the extract of an
ethanolic fraction of Origanum majorana inhibited the proliferation of
the mutant p53 triple negative breast cancer (TNBC) cell line,
MDA-MB-231. We have also demonstrated that OME induces a
differential concentration-dependent effect on these cells. OME
induces a cell cycle arrest at G2/M phase and more precisely a
mitotic arrest at low concentrations. This finding is supported by a
body of evidence: (i) increase in the level of p(ser10)H3, a mitotic
marker, and (ii) an increase of cyclin B1 protein level, whose
upregulation was reported in several mitotically arrested cells. We
have also shown that the cell cycle arrest correlates with an
upregulation of the CDK inhibitor p21 and the anti-apoptotic
protein, survivin. At high concentrations, however, OME induced
a massive apoptosis demonstrated by a dramatic increase in the
sub-G1 population. We have demonstrated that OME exerts its
apoptotic effect by activating the cell death extrinsic pathway is
mediated, at least partially, via the activation of TNF-a. We have
also shown that OME-induced apoptosis is also mediated by an
increase in DNA damage, revealed by an upregulation of cH2AX,
severe depletion of the mutant p53 and survivin proteins from the
treated cells.
The process of apoptosis can be induced either by the extrinsic
pathway which involves signalling from death receptors at the cell
surface or by the intrinsic mitochondria-mediated pathway [24].
Activation of the death receptor-mediated apoptosis requires the
interaction of the ligands such as TNF-a and Fas with their
transmembrane receptors [25]. The ligand-receptor interaction
leads to the activation of the effector caspase 8, which in turn
activates the effector caspase 3 directly and/or through mito-
chondria [26]. The mitochondria-mediated apoptosis pathway is
associated with permeabilization of the mitochondria outer
membrane, reduced mitochondrial membrane potential (Dym),
change in expression of the anti-apoptotic Bcl2 family members,
such as Bcl2 and Bcl-XL and the pro-apoptotic members such as
Bax and Bak leading to the formation of the apoptosome,
activation of caspase 9 and consequently activation of caspase 3
[27]. Intrinsic- and extrinsic-pathaways activated caspase 3 cleave
poly(ADP-ribose) polymerase (PARP), thus resulting in apoptosis
[28]. In the present study, we showed that OME induced TNF-a-
mediated extrinsic apoptotic pathway. TNF-a receptor was
activated at 24 h and induced downstream signalling such as
caspase 8, caspase 3, and PARP cleavage. On the other hand,
OME did not induce mitochondria-mediated apoptotic pathway
since no change in the BAX/Bcl2 ratio or activation of caspase 9
were detected. We suggest that OME induces apoptosis solely
through TNF-a activated signal pathway in MDA-MB-231 cells.
Studies have reported that DNA damage is one of the molecular
events associated with cell cycle arrest and apoptosis. Indeed, and
many anti-cancer drugs have been shown to induce DNA damage
[29,30]. Moreover, cancer cells are reported to be more
susceptible than normal cells to DNA damaging agents [31],
therefore there is a growing interest in dietary phytochemicals that
possess DNA-damaging activity. In the present study we showed
that OME elicited DNA damage measured by an increase in a
concentration-dependent manner of the marker of DNA damage,
c-H2AX, after treatment with OME for 6 or 24 h. The differential
response to the different concentrations of OME (G2/M arrest
and/or apoptosis), may be partially mediated by the extent of
DNA damage occurred within the genome. Low levels of DNA
damage may trigger recruitment of DNA repair complexes,
expression of anti-apoptotic and survival proteins leading to
arrested cell cycle until the genotoxic lesions are repaired. In this
case, survival protein such as survivin gets activated in order to
maintain the viability of G2/M arrested cells. On the other hand,
when genomes are overwhelmed by DNA damage, cells are
eliminated by apoptosis [32,33]. In this study, we have found that
high concentrations of OME triggered high level of DNA damage
to the genome, causing cell to enter apoptosis. Our data suggest
that Origanum majorana possess a genotoxic effect on MDA-MB-231
cells. At this stage, the mechanism(s) by which OME induces DNA
damage remain(s) unknown, and certainly deserves further studies.
Inhibitor of apoptosis proteins (IAPs), which includes survivin,
represents a family of anti-apoptotic proteins that bind and
inactivate active caspase 3, 7 [34,35] and caspase 9 [36] and can
modulate cell division and cell cycle progression [37].
Interestingly, survivin has no effect on caspase 8 activity.
Survivin has been shown to be highly expressed in most cancers,
where it functions as inhibitor of apoptosis. In breast cancer,
overexpressed survivin was shown to protect cells against apoptosis
induced by chemotherapeutic agents, such as etoposide [34].
Based on these reports, survivin protein represents an attractive
target of particular importance in cancer therapy at large and in
breast cancer therapy in particular. In consideration of the
recognized role for survivin as a custodian of cancer cell survival,
our results suggest that OME might exert its cytotoxic anti-cancer
effects at least partly via the down-regulation of survivin. In our
study, we have shown that survivin expression is differentially
regulated in a concentration-dependent manner by OME. Lower
concentrations of OME induced an upregulation of survivin which
causes cells to arrest the cell division and to resist apoptosis by
inhibiting the cell death program. In fact, we showed that in these
arrested cells, PARP cleavage was not detected despite the
activation of caspase 3/7. This effect might be mediated by the
inhibition of active 3/7 by the upregulated survivin. Survivn
function could also account for the mitotic arrest induced by
OME. In fact, Survivin, has also been shown to be required for
mitotic arrest of Hela cells induced by the anticancer drug UCN-
01 [38].
The tumor suppressor protein, p53 is found to be mutated in
about 50% of human cancers [39]. Mutant p53 is reported to play
a key role in cancer cells resistance to certain anticancer drugs and
Figure 6. O. majorana induces hyperacetylation of histone H3 (AcH3) and H4 (AcH4). (A) Protein levels of Ac-H3 and Ac-H4, extracted from
OME-treated cells, were detected by western blot using antibodies specific for the modified histone (Ac-H3) and Ac-H4. b-actin was used as loading
control. (B) Immunofluorescence staining of Ac-H3 and Ac-H4 in MDA-MB231 cells treated with 150, 300 and 450 mg/mL of OME or equal volume of
vehicle (ethanol) as control for 24 h. Cells were fixed, permeabilized, and then processed for immunofluorescence using antibodies against the
indicated modified histones. DAPI was used as a nuclear stain.
doi:10.1371/journal.pone.0056649.g006
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thus is considered as a potential cancer-specific target for
pharmacologic interventions [40,41]. Studies have shown that
inhibition of mutant p53 by RNA interference sensitizes cancer
cell to cell death by chemotherapeutic agents [42]. Wang et al.
2011, showed that the naturally occurring isothiocyanates (ITCs)
phenetyl isoisothiocyanate (PEITC), derived from watercress
plant, and the synthetic ITC, 2,2-di phenetyl isoisothiocyanate
selectively deplete mutant, but not the wild-type p53, and induce
apoptosis in many cancer cells, including the MDA-MB-231 breast
cancer cells [43]. Here, we showed that OME led to dramatic
decrease in the mutant p53 level in MDA-MB-231 cells. As such,
mutant p53 depletion may be an important target for chemopre-
vention and therapy by O. majorana for TNBC.
Increase in the expression of the cyclin-dependent kinase
inhibitor, p21 has been shown to augment G2/M arrest via a
p53-independent mechanism in human breast cancer [44]. In
most cases, growth arrest was found to be associated with
apoptosis. In this study, we showed that low concentrations of
OME treatment led to G2/M arrest without significant increase in
cell death after 24h treatment. Histone hyperacetylation has been
demonstrated to be directly linked to the upregulation of p21 and
this activation can also occur independently of p53 [45].
Moreover, histone hyperacetylation was also shown to be
associated with growth suppression and apoptosis. Our data
showed that OME induced histone H3 and H4 hyperacetylation
in MDA-MB-231 cells, suggesting that the anti-breast cancer
effects of OME were at least partly mediated by histone H3 and
H4 hyperacetylation by regulating the expression of the genes
controlling these two events. The mechanism by which OME
induces histone hyperacetylation might involve a histone deace-
tylase inhibitor (HDI) activity. Interestingly, the plant, O. majorana,
contains luteolin, a dietary flavonoid with HDI activity [14]. In
Figure 7. O. majorana extract induces a dose-dependent activation of cH2AX, a marker of DNA double-strands breaks, in MDA-MB
231 cells. (A) Western blot analysis of phosphor-H2AX (ser 139) in MDA-MB231 cells exposed for 6 and 24h with the indicated concentrations of OME
or equal volume of vehicle (ethanol) as control. (B) Immunofluorescence staining for cH2AX in OME-treated MDA-MB 231cells. Cells were treated with
vehicle or 150, 300 and 450 mg/mL extract for 24 h, fixed, permeabilized, and then processed for immunofluorescence using antibodies against p-
H2AX (ser 139) protein. DAPI was used as a nuclear stain.
doi:10.1371/journal.pone.0056649.g007
Figure 8. Inhibition of colony growth by O. majorana extract. Inhibition of colony growth was assessed by measuring the size of the colonies
obtained in vehicle (ethanol)- and OME-treated plates. Data were compared with those obtained for the 2 weeks colonies. Two types of colonies were
counted and depending on their diameter were categorized as large ($200 mm) and small (,2002$50 mm).
doi:10.1371/journal.pone.0056649.g008
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fact, luteolin was able to decrease the viability of lung, colon, liver
and breast cancer cells and induce hyperacetylation of histone H3
and H4 [46]. In light of these data, we conclude that the histone
hyperacetylation induced by OME is involved with the HDI
activity of luteolin. We are currently undertaking further
investigations to better understand the mechanim(s) by which
OME induces histone hyperacetylation.
In conclusion, our data are consistent with a model shown in
figure 9 which shows the concentration-dependent differential
effect of O.majorana extract on mutant p53, triple negative MDA-
MB-231 cells. At low concentrations, OME induced a mitotic
arrest associated with low level of DNA damage (Figure 9, thin
arrow), upregulation of the CDK inhibitor p21 and the inhibitor of
apoptosis, survivin. We believe that these events along with other
‘‘yet to be identified’’ events contribute to the cell cycle arrest. In
addition we also propose that, at these concentrations, survivn is
also implicated in the blockade of the TNF-mediated apoptosis
pathway, by directly inhibiting the activity of the active caspase 3.
On the other hands, high concentrations, OME induce massive
apoptosis via the activation of the TNF-a extrinsic pathway which
is associated with high level of DNA damage (Figure 9, thick
arrow) and almost complete depletion of the mutant p53 and
surviving proteins from these cells. Our findings provide the first
instance of a potential role for OME as an anti-breast cancer
agent in vitro which certainly deserves more attention for further
explorations to identify novel compounds for breast cancer.
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